title: Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.
abstract: For rapid and effective clinical translation, polymer-based anticancer therapeutics need long circulating conjugates that produce a sustained concentration gradient between the vasculature and solid tumor. To this end, we designed second-generation backbone-degradable diblock N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carriers and evaluated sequential combination therapy of HPMA copolymer-paclitaxel and HPMA copolymer-gemcitabine conjugates against A2780 human ovarian carcinoma xenografts. First, extensive in vitro assessment of administration sequence impact on cell cycle, viability, apoptosis, migration, and invasion revealed that treatment with paclitaxel conjugate followed by gemcitabine conjugate was the most effective scheduling strategy. Second, in an in vivo comparison with first-generation (nondegradable, molecular weight below the renal threshold) conjugates and free drugs, the second-generation degradable high-molecular weight conjugates showed distinct advantages, such as favorable pharmacokinetics (three- to five-times half-life compared with the first generation), dramatically enhanced inhibition of tumor growth (complete tumor regression) by paclitaxel and gemcitabine conjugate combination, and absence of adverse effects. In addition, multimodality imaging studies of dual-labeled model conjugates confirmed the efficacy of second-generation conjugates by visualizing more than five-times enhanced tumor accumulation, rapid conjugate internalization, and effective intracellular release of payload. Taken together, the results indicate that the second-generation degradable HPMA copolymer carrier can provide an ideal platform for the delivery of a range of antitumor compounds, which makes it one of the most attractive candidates for potential clinical application.
authors.affiliation: Department of Pharmaceutics and Pharmaceutical Chemistry, Center for Controlled Chemical Delivery, and.
authors.forename: Rui
authors.initials: R
authors.lastname: Zhang
authors.affiliation: Department of Pharmaceutics and Pharmaceutical Chemistry, Center for Controlled Chemical Delivery, and.
authors.forename: Jiyuan
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Pharmaceutics and Pharmaceutical Chemistry, Center for Controlled Chemical Delivery, and.
authors.forename: Monika
authors.initials: M
authors.lastname: Sima
authors.affiliation: Department of Pharmaceutics and Pharmaceutical Chemistry, Center for Controlled Chemical Delivery, and.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Pharmaceutics and Pharmaceutical Chemistry, Center for Controlled Chemical Delivery, andDepartment of Bioengineering, University of Utah, Salt Lake City, UT 84112 Jindrich.Kopecek@utah.edu.
authors.forename: Jindřich
authors.initials: J
authors.lastname: Kopeček
mesh_terms: D000178:Acrylamides / Q000737:chemistry*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002453:Cell Cycle; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
chemical_list: D000178:Acrylamides; D003841:Deoxycytidine; D017239:Paclitaxel; C032976:N-(2-hydroxypropyl)methacrylamide; D000093542:Gemcitabine
keywords: EPR effect; dual-isotope label; macromolecular therapeutics
references.citation: Biomacromolecules. 2011 Jan 10;12(1):247-52
references.pmid: 21158387
references.citation: Adv Drug Deliv Rev. 2013 Jan;65(1):49-59
references.pmid: 23123294
references.citation: Adv Drug Deliv Rev. 2010 Feb 17;62(2):122-49
references.pmid: 19919846
references.citation: Science. 2008 Feb 8;319(5864):810-3
references.pmid: 18174397
references.citation: J Control Release. 1998 Apr 30;53(1-3):25-37
references.pmid: 9741911
references.citation: Biol Chem. 2003 Jun;384(6):845-54
references.pmid: 12887051
references.citation: Cancer Biol Ther. 2006 Aug;5(8):1015-21
references.pmid: 16855376
references.citation: J Biomed Mater Res. 1987 Nov;21(11):1341-58
references.pmid: 3680316
references.citation: Biomaterials. 1990 Sep;11(7):455-64
references.pmid: 2242394
references.citation: React Funct Polym. 2011 Mar 1;71(3):294-302
references.pmid: 21499527
references.citation: J Nucl Med. 1989 Mar;30(3):374-84
references.pmid: 2738666
references.citation: J Clin Oncol. 2011 Dec 1;29(34):4548-54
references.pmid: 21969517
references.citation: J Clin Oncol. 2002 Mar 15;20(6):1668-76
references.pmid: 11896118
references.citation: Eur J Cancer. 2001 Jan;37(1):131-9
references.pmid: 11165140
references.citation: Cancer Biol Ther. 2005 Aug;4(8):866-71
references.pmid: 16210917
references.citation: Ann Oncol. 2009 Mar;20(3):449-53
references.pmid: 19087987
references.citation: Cancer Chemother Pharmacol. 2008 Aug;62(3):457-64
references.pmid: 18008070
references.citation: Pharm Res. 1999 Jul;16(7):986-96
references.pmid: 10450921
references.citation: Mol Pharm. 2010 Aug 2;7(4):922-5
references.pmid: 20672864
references.citation: J Control Release. 2004 Dec 10;100(3):331-46
references.pmid: 15567500
references.citation: Lung Cancer. 2006 Dec;54(3):359-64
references.pmid: 17028052
references.citation: Cancer Res. 1996 May 1;56(9):2112-5
references.pmid: 8616858
references.citation: Adv Enzyme Regul. 1984;22:27-55
references.pmid: 6382953
references.citation: Biomaterials. 1985 Jan;6(1):45-8
references.pmid: 3971018
references.citation: Gynecol Oncol. 2003 Aug;90(2 Pt 2):S16-20
references.pmid: 12928001
references.citation: Macromolecules. 2011 Apr 26;44(8):2481-2488
references.pmid: 21552355
references.citation: Gynecol Oncol. 2004 Mar;92(3):881-6
references.pmid: 14984956
references.citation: Bioconjug Chem. 2010 May 19;21(5):797-802
references.pmid: 20397686
references.citation: Int J Oncol. 2009 Jun;34(6):1629-36
references.pmid: 19424581
references.citation: Semin Oncol. 2000 Jun;27(3 Suppl 7):3-7
references.pmid: 10952119
references.citation: Cancer Res. 2001 Apr 15;61(8):3493-500
references.pmid: 11309313
references.citation: J Clin Oncol. 1999 Jul;17(7):2190-7
references.pmid: 10561275
references.citation: Int J Oncol. 2008 Jan;32(1):113-20
references.pmid: 18097549
references.citation: J Control Release. 1998 Jul 31;54(2):223-33
references.pmid: 9724909
references.citation: Clin Cancer Res. 1999 Jan;5(1):83-94
references.pmid: 9918206
references.citation: J Clin Oncol. 1997 Jan;15(1):310-6
references.pmid: 8996158
references.citation: JOP. 2013 Nov 10;14(6):686-8
references.pmid: 24216565
references.citation: Br J Cancer. 2000 Oct;83(8):1069-76
references.pmid: 10993656